Given that Cav3.1 is an emerging target for treating Dravet syndrome, we conducted more detailed patch-clamp electrophysiology studies to illuminate the biophysical properties of the inhibitory effects at this channel. This evidence concerns the gene CACNA1G and Dravet syndrome.